CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration

Taeyoung Koo; Sung Wook Park; Dong Hyun Jo; Daesik Kim; Jin Hyoung Kim; Hee-Yeon Cho; Jeungeun Kim; Jeong Hun Kim; Jin-Soo Kim

doi:10.1038/s41467-018-04175-y

Nature Communications (May 2018)

CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration

Taeyoung Koo,
Sung Wook Park,
Dong Hyun Jo,
Daesik Kim,
Jin Hyoung Kim,
Hee-Yeon Cho,
Jeungeun Kim,
Jeong Hun Kim,
Jin-Soo Kim

Affiliations

Taeyoung Koo: Center for Genome Engineering, Institute for Basic Science
Sung Wook Park: FARB Laboratory, Biomedical Research Institute, Seoul National University Hospital
Dong Hyun Jo: FARB Laboratory, Biomedical Research Institute, Seoul National University Hospital
Daesik Kim: Department of Chemistry, Seoul National University
Jin Hyoung Kim: FARB Laboratory, Biomedical Research Institute, Seoul National University Hospital
Hee-Yeon Cho: Center for Genome Engineering, Institute for Basic Science
Jeungeun Kim: Department of Chemistry, Seoul National University
Jeong Hun Kim: FARB Laboratory, Biomedical Research Institute, Seoul National University Hospital
Jin-Soo Kim: Center for Genome Engineering, Institute for Basic Science

DOI: https://doi.org/10.1038/s41467-018-04175-y
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 8

Abstract

Read online

The CRISPR endonuclease LbCpf1 is reported to have greater efficiency and specificity than Cas9. Here, the authors use LbCpf1 to target the angiogenesis-related genes VEGF and HIF1a, and show that delivery of the nuclease using AAV9 is effective in mouse models of macular degeneration.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal